Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of cabozantinib S-malate in
treating younger patients with solid tumors that have come back or no longer respond to
treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.